Alnylam and Isis Pharmaceuticals announced an intellectual property cross-licensing agreement that they hope will leave them both better equipped to deal with the challenges of developing the first commercial RNAi therapy, including utilization of the promising but still-unproven RNA interference drug delivery pathway, and sometimes jittery investors.
Oncology biotech Mersana Therapeutics has expanded its relationship with Takeda, forging an agreement to develop targeted cancer drugs with as much as $300 million on the line.
Oracle announced that it will deploy Proteus' digital pill into its clinical trial data capture and management solution to track patient adherence to dosing instructions during trials, and provide insights into drug efficacy and safety. The development at the gargantuan JP Morgan Healthcare Conference in San Francisco is another win for ingestible devices, as well as Proteus, the recipient of a $172 million Series G financing in July last year.
Evotec, a risk-sharing R&D collaborator, has extended its relationship with biotech startup Padlock Therapeutics, inking a new deal that will see the pair progress into preclinical development.
X-Chem, a subsidiary of PPD, has signed a deal with Johnson & Johnson to provide its library of molecules to aid in the discovery of new treatments for inflammatory disease.
Genentech has given 23andMe a major boost. The big biotech has reportedly paid $10 million upfront and agreed to $50 million in milestones to access 23andMe's database for target discovery of new drugs for Parkinson's disease.
Bristol-Myers Squibb's standout immuno-oncology drug nivolumab, approved last month as Opdivo, scored a resounding success in a late-stage lung cancer trial, bolstering sales expectations for the pioneering treatment.
Some of the cash will go toward creating a sequencing and analysis center at Columbia to support collaborative research.
Incyte is jumping aboard Agenus' antibody discovery platform, signing up to partner on new immuno-oncology drugs with $60 million in cash and promises of up to $350 million in milestones. And the deal news quickly drove up Agenus' shares by more than 30% in premarket trading.
Pfizer appears to be speeding toward a crucial early FDA approval for palbociclib, a breast cancer treatment with blockbuster potential, pivoting from its failed bid for AstraZeneca and building up an oncology pipeline of its own.